1. Кан Д.В., Сегал А.С., Кузьменко А.Н. Диагностика и лечение хронического неспецифического простатита. Методические рекомендации. М., 1980; с. 30.
2. Тиктинский О.Л. Воспалительные заболевания мочеиспускательного канала, предстательной железы, семенных пузырьков и семенного бугорка. Руководство по андрологии. Л., 1990; с. 54–97.
3. Лопаткин Н.А. Руководство по урологии. 1998; 2: 393–440.
4. Moon TD. Diagnostic and treatment practices for prostatitis by urologists and primary care physicians. J Urol 1997; 157: 242A.
5. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159: 1224–8.
6. Nickel JC. Prostatitis: myths and realities. Urology 1998; 51: 362–6.
7. Schaeffer AJ, Anderson, Krieger JN et al. WHO Consultation, Paris 2005.
8. Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 281: 236–7.
9. Wagenlehner FM, Naber KG. Prostatitis: the role of antibiotic treatment. World J Urol 2003; 21 (2): 105–8.
10. Meares EM, Stamey TA. Bacteriological localization patterns in bacterial prostatitis and uretritis. Invest Urol 1968; 5: 492–518.
11. Nickel JC, Shoskes D, Wang Y et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol 2006; 176: 119–24.
12. Schaeffer AJ, Weidner W, Barbalis GA. Summary Consensus Statement: Diagnosis and Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Eur Urol 2003; Suppl. 2: 1–4.
13. Pavone-Macaluso M. Chronic prostatitis syndrome: a common, but poorly understood condition. Part I. EAU-EBU update series 2007; 5: 1–15.
14. Naber KG, Weidner W. Chronic prostatitis – an infectious disease? J Antimicrob Chemother 2000; 46: 157–61.
15. Naber KG, Busch W, Focht J, the German Prostatitis Study Group. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, noncomparative multicentre clinical trial with long-term follow-up. Int J Antimicrob Agents 2000; 14: 143–9.
16. Krieger JN, Ross SO, Limaye AP, Riley DE. Inconsistent localisation of grampositive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology 2005; 66: 721–5.
17. Weidner W, Diemer T, Huwe P et al. The role of Chlamydia trachomatis in prostatitis. Int J Antimicrob Agents 2002; 19: 466–70.
18. Weidner W, Schiefer HG, Kraus H et al. Chronic prostatitis a through search for etiologically involved microorganisms in 1461 patients. Infection 1991; 19 (suppl. 3): 119–25.
19. Лоран О.Б., Пушкарь Д.Ю., Сегал А.С., Юдовский С.О. Наше понимание хронического простатита. Фарматека. 2002; 10: 69–75.
20. Naber KG. Role of quinolones in treatment of chronic bacterial prostatitis. Quinolone Antimicrobial Agents. Eds. D.C.Hooper, J.Wolfson – American Society for Microbiology. Washington D.C. USA, 1993; p. 285–97.
21. Naber KG, Sorgel F. Antibiotic therapy – rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003; 35 (5): 331–5.
22. Pavone-Macaluso M. Chronic prostatitis syndrome: a common, but poorly understood condition. Part II. EAU-EBU update series 2007; 5: 16–25.
23. Naber KG, Bishop MC, Bjerklund-Johansen TE et al. Guidelines on the management of urinary and male genital tract infections. Eur Assoc of Urology. 2006.
24. Drusano GL, Preston SL, Van Guilder M et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000; 44 (8): 2046–51.
25. Trinchiere A. Role of levofloxacin in the treatment of urinary tract infections. Arch Ital Urol Androl 2001; 73 (2): 105–13.
26. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63 (24): 2768–802.
27. Naber KG. Levofloxacin in the treatment of urinary tract infection and prostatitis. J Chemother 2004; 16 (Suppl. 2): 18–21.
28. Bulitta J, Kinzig-Schippers M, Naber CK et al. Limitations in the use of drug cocktails to compare the pharmacokinetics of drugs: ciprofloxacin versus levofloxacin. 40th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), Toronto, Canada, 17–20 September 2000 (poster no. 506).
29. Bundrick W, Heron SP, Ray P et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003; 62 (3): 537–41.
30. Мазо Е.Б., Ковальчук Л.В., Ганковская Л.В. и др. Эффективность применения Суперлимфа в комплексном лечении хронического бактериального простатита и воспалительного синдрома хронической тазовой боли. Материалы 3-й Всероссийской конференции «Мужское здоровье». М., 2006; с. 72–3.
31. Naber KG, Roscher K, Botto H, Schaefer V. Oral levofloxacin 500mg once daily in the treatment of chronic bacterial prostatitis. International J Antimicrob Agents 2008 Jun 19. [Epub ahead of print]
32. Giannarini G, Mogorovich A, Morelli G et al. Chronic bactierial prostatitis: a prosective, randomized, double-blinde triale. AUA Annual Meeting, Anaheim May 19–24, 2007 (abstr. 99).
33. Jeong CW, Lim DJ, Son H et al. Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urol Int 2008; 80 (2): 157–61.
34. Tal R et al. Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy. J Urol 2003; 169: 1762–5.
35. Shigehara K, Miyagi T, Nakashima T, Shimamura M. Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis. J Infect Chemother 2008; 14 (1): 40–3. Epub 2008 Feb 24.
36. Briffaux R et al. One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy. BJU International 2008; 103: 1069–73.
37. Hoshi A et al. Sepsis following transrectal prostate biopsy: a report of 2 cases and reviewed similar cases in Japan. Hinyokika Kiyo 2006; 52 (8): 645–9.
38. Miura T, Tanaka K, Shigemura K et al. Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. Int J Urol 2008; 15 (5): 457–9.
39. Scotton PG et al. Which antibiotic prophylaxis to use for urologic procedures at risk for infective endocarditis: a report on two cases. Infez Med 2006; 14 (4): 246–7.
40. Feliciano J, Teper E, Ferrandino M et al. The incidence of fluoroquinolone resistant infections after prostate biopsy – are fluoroquinolones still effective prophylaxis? J Urol 2008; 179 (3): 952–5.
41. Griffith BC, Morey AF, Ali-Khan MM et al. Single dose levofloxacin prophylaxis for prostate biopsy in patients at low risk. J Urol 2002; 168 (3): 1021–3.
42. Берников А.Н., Раснер П.И., Говоров А.В., Бормотин А.В. Профилактическая антибактериальная терапия при трансректальной биопсии предстательной железы. Фарматека. 2002; 10: 59–60.
43. Говоров А.В., Пушкарь Д.Ю, Зайцев А.В., Курджиев МА. Антибактериальная профилактика левофлоксацином при трансректальной биопсии предстательной железы – новый стандарт? Материалы Всероссийской научно-практической конференции «Современные принципы диагностики, профилактики и лечения инфекционно-воспалительных заболеваний почек, мочевыводящих путей и половых органов». М., 8–9 февраля 2007; с. 34–5.
44. Yamamoto S, Ishitoya S, Segawa T et al. Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin. Int J Urol 2008; 15 (7): 604–6.